-
Mashup Score: 1
Curious to learn more about the SOAP process, but too afraid to ask? Join those who have undergone the process as they give you the nuts and bolts of the pro…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline - 4 month(s) ago
PURPOSE To develop recommendations for germline mutation testing for patients with breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. RESULTS Forty-seven articles met eligibility criteria for the germline mutation testing recommendations; 18 for the genetic counseling recommendations. RECOMMENDATIONS BRCA1/2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and select patients >65 years based on personal history, family history, ancestry, or eligibility for poly(ADP-ribose) polymerase (PARP) inhibitor therapy. All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, regardless of family history. BRCA1/2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralateral breast. For patients with prior history of breast canc
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22Beyond bacteria: How the intratumor mycobiome modulates lung adenocarcinoma progression - 7 month(s) ago
Increasing evidence suggests that tumors harbor diverse microbiomes, adding complexity to the tumor microenvironment. In this issue of Cancer Cell, Liu et al. highlight the role of the intratumor mycobiome, specifically Aspergillus sydowii, in promoting lung adenocarcinoma progression. A. sydowii enhances the recruitment and activation of myeloid-derived suppressor cells via IL-1β signaling driven by the β-glucan-mediated Dectin-1/CARD9 pathway.
Source: www.cell.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1
KEYTRUDA® (pembrolizumab) plus chemotherapy before surgery significantly improved pCR rate compared to neoadjuvant placebo plus chemotherapy KEYNOTE-756 is the first positive Phase 3 study with an immunotherapy regimen to demonstrate a statistically significant improvement in pCR rate in the neoadjuvant setting for this patient population Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete response (pCR) rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen in patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. At a prespecified interim analysis conducted by an independent Data Monitoring Committee (DMC), the KEYTRUDA-based regimen demonstrated a
Source: www.merck.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 4THE ONCOALERT NETWORK - 11 month(s) ago
Welcome to OncoAlert
Source: THE ONCOALERT NETWORKCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0WHO ends global health emergency declaration for COVID-19 - 1 year(s) ago
The World Health Organization today lifted its Public Health Emergency of International Concern for COVID-19. That declaration went into effect three years ago on Jan. 30, 2020.
Source: NPRCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer | Eli Lilly and Company - 1 year(s) ago
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: Eli Lilly and CompanyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Montefiore Einstein Announces $100 Million Contribution to Albert Einstein College of Medicine | Albert Einstein College of Medicine - 1 year(s) ago
Montefiore Einstein receives $100 million anonymous contribution to support biomedical and translational research programs serving nation and the world.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5The 2022 OncoAlert Colloquium DAY 1: Breast Cancer - 1 year(s) ago
A warm welcome to the third OncoAlert ColloquiumThis year being held in partnership with: The American Society for Radiation OncologyThe European Cancer Orga…
Source: YouTubeCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 8The 2022 OncoAlert Colloquium DAY 1: Breast Cancer - 1 year(s) ago
A warm welcome to the third OncoAlert ColloquiumThis year being held in partnership with: The American Society for Radiation OncologyThe European Cancer Orga…
Source: YouTubeCategories: Latest Headlines, Oncologists2Tweet
RT @ecalhoun21: https://t.co/ERExaJw1OV @aaeminfo WiEM webinar relevant this week for any #unmatched #embound 4th years.